Changes in metformin use in chronic kidney disease

Clinical Kidney Journal

Volumn 10, Issue 3, 2017, Pages 301-304

  Imam, Talha H ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

chronic renal insufficiency; diabetes mellitus; lactic acidosis; metformin

Indexed keywords

METFORMIN;

CHRONIC KIDNEY FAILURE; DRUG CONTRAINDICATION; DRUG USE; FEAR; HUMAN; INCIDENCE; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 85033602329     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfx017     Document Type: Review

References (40)

1. Werner E, Bell J. The preparation of methylguanidine, and of bb-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans 1921; 121: 1790-1795
2. Sterne J. Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanide (N.N.D.G.). Maroc Med 1957; 36: 1295-1296
3. Ungar G, Freedman L, Shapiro SL. Pharmacological studies of a new oral hypoglycaemic drug. Proc Soc Exp Biol Med 1957; 100: 190-192
4. Mehnert H, Seitz W. Weitere Ergebnisse der diabetesbehandlung mit blutzuckersenkenden biguaniden. Munch Med Wschr 1958; 100: 1849-1851
5. Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: A meta-analysis. Diabetes Metab Rev 1995; 11: S57-S62
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
7. International Diabetes Federation. Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. 2012. http://www. idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes. pdf (18 December 2015, date last accessed)
8. World Health Organization. http://www.who.int/medicines/ publications/essentialmedicines/18th_EML.pdf (18 December 2015, date last accessed)
9. Terpening C. MALAdaptive: Do we avoid metformin unnecessarily?. J Am Board Fam Med 2014; 27: 136-141
10. Misbin RI, Green L, Stadel BV et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265-266
11. Bodmer M, Meier C, Kr€ahenbühl S et al. Metformin, sulfonylureas, or other antidiabeties drugs and the risk of lactic acidosis or hypoglycemia. Diabetes Care 2008; 31: 2086-2091
12. Swift TMM. Metformin use in patients with diabetes and heart failure: Cause for concern?. Diabetes Spectr 2009; 22: 18-20
13. Taharani AA, Varughese GI, Scarpello JH et al. Metformin, heart failure, and lactic acidosis: Is metformin absolutely contraindicated?. BMJ 2007; 335: 508-512
14. Holstein A, Nahrwold D, Hinz S et al. Contra-indications to metformin therapy are largely disregarded. Diabetic Med 1999; 16: 692-696
15. Salpeter SR, Greyber E, Pasternak GA et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Review). Cochrane Database Syst Rev 2010; 1: CD002967. DOI: 10.1002/14651858.CD002967.pub4.
16. Heaf JG, Biesen EV. Metformin and chronic renal impairment: A story of choices and ugly ducklings. Clin Diabetes 2011; 29: 97-101
17. Aguilar C, Reza A, Garcia JE et al. Biguanide related lactic acidosis: Incidence and risk factors. ArchMed Res 1992; 23: 19-24
18. Stang MR, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22: 925-927
19. Metformin Package Insert. Princeton, NJ: Bristol-Myers Squibb, 2008
20. National Kidney Foundation. KDOQI Clinical practice guidelines for diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60: 850-886
21. Lalau JD, Vermersh A, Hary L et al. Type 2 diabetes in the elderly: An assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990; 28: 329-332
22. Duong JK, Roberts DM, Furlong TJ et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab 2012; 14: 963-965
23. Rachmani R, Slavachevski I, Levi Z et al. Metformin in patients with type 2 diabetes mellitus: Reconsideration of traditional contraindications. Eur J Intern Med 2002; 13: 428-433
24. Frid A, Sterner GN, LöndahlMet al. Novel assay of Metformin levels in patients with type 2 diabetes and varying levels of renal function: Clinical recommendations. Diabetes Care 2010; 33: 1291-1393
25. Roussel R, Travert F, Pasquet B et al. Reduction of atherosclerosis for continued health (REACH) registry investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170: 1892-1899
26. Ekström N, Schiöler L, Svensson A-M et al. Effectiveness and safety of metformin in 51675 patients with type 2 diabetes and different levels of renal function: A cohort study from Swedish National Diabetes Register. BMJ Open 2012; 2: E001076
27. Colagiuri S, Dickinson S, Girgis S et al. National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes. Canberra: Diabetes Australia and the NHMRC, 2009. http://www. nhmrc.gov.au/_files_nhmrc/publications/attachments/di19-diabetes-blood-glucose-control.pdf (18 December 2015, date last accessed)
28. Canadian Diabetic Association. Clinical Practice Guideline. 2013 http://guidelines.diabetes.ca/App_Themes/CDACPG/resources/ cpg_2013_full_en.pdf (18 December 2015, date last accessed)
29. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: A patient centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
30. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437
31. Inzucchi SE, Lipska KJ, Mayo H et al. Metformin in patients with type 2 diabetes and kidney disease. A systemic review. JAMA 2014; 312: 2668-2675
32. European Medicines Agency, London, UK. Use of Metformin to Treat Diabetes Now Expanded to Patients with Moderately Reduced Kidney Function. 2016 EMA/603690/2016. http://www.ema. europa.eu/docs/en_GB/document_library/Referrals_docu ment/Metformin_31/WC500214235.pdf (5 December 2016, date last accessed)
33. Clinical practice guidelines on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR _ 45ml/min). Nephrol Dial Transplant 2015; 30: Ii1-ii142.
34. Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group. KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150.
35. Mani MK. Metformin in renal failure: weigh the evidence. Nephrol Dial Transplant 2009; 24: 2287-2288
36. Campbell IW. Metformin and glibenclamide: Comparative risks. BMJ 1984; 289: 89
37. Lalau JD, Arnouts P, Sharif A et al. Metformin and other antidiabetic agents in renal failure patients. Kidney Int 2015; 87: 308-322
38. Kajbaf F, Lalau D. Mortality rate in so-called 'metforminassociated lactic acidosis': A review of the data since the 1960s. Pharmacoepidemiol Drug Saf 2014; 23: 1123-1127
39. Imam TH. Metformin and kidneys-A contentious relationship. Austin J Nephrol Hypertens 2014; 1: 1012
40. US Food and Drug Administration, Silver Spring, MD. FDA Drug Safety Communication: FDA Revises Warnings Regarding Use of the Diabetes Medicine Metformin in Certain Patients with Reduced Kidney Function. 2016 http://www.fda.gov/downloads/Drugs/ DrugSafety/UCM494140.pdf (5 December 2016, date last accessed)